Health

UnitedHealth Group (UHG) has emerged as a dominant force in the healthcare industry, with nearly $400 billion in revenue and $22.4 billion in profits in 2023 alone. This financial success has been achieved through vertical integration, allowing UHG to control everything from health insurance to pharmaceuticals. This level of control raises concerns about the impact
0 Comments
Amblyopia, commonly referred to as “lazy eye,” has been linked to an increased risk of cardiometabolic disorders in adulthood, according to a recent observational cohort study conducted by researchers at University College London’s (UCL) Great Ormond Street Institute of Child Health. The study, which involved individuals over the age of 40 living with amblyopia, revealed
0 Comments
A recent Phase II randomized controlled trial has shown promising results for a novel fixed-dose combination of alpibectir-ethionamide in patients with tuberculosis (TB). The trial demonstrated similar levels of bactericidal activity to isoniazid, a commonly used anti-TB drug, with no serious adverse events and good tolerability. It is essential to find new treatment options for
0 Comments
The integration of artificial intelligence (AI) into healthcare settings, specifically in clinician-patient conversations, raises serious concerns regarding security and privacy issues. While AI has the potential to streamline processes and improve patient care, the lack of clarity surrounding data protection and confidentiality is a significant barrier to its widespread adoption. The announcement of a new
0 Comments
The recent data from the CDC’s IVY and VISION networks have shed light on the protection provided by the newly updated COVID vaccines against severe virus-related outcomes in immunocompetent adults. According to Jennifer DeCuir, MD, PhD, and colleagues, the vaccine effectiveness (VE) against COVID-related emergency department or urgent care encounters ranged from 47% to 52%,
0 Comments
A recent study presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) forum revealed that patients with relapsing multiple sclerosis (RMS) who were continuously treated with ozanimod (Zeposia) for 7 to 8 years exhibited stable or improved clinical and radiologic measures of disease activity. Regardless of the age category, the adjusted
0 Comments
Obesity is a significant health concern worldwide, with numerous associated risks and complications. Recent research has highlighted a potential link between obesity and the progression of multiple sclerosis (MS). A prospective cohort study conducted by Lars Alfredsson, PhD, at the Karolinska Institute in Stockholm, Sweden, presented findings at the ACTRIMS Forum 2024, shedding light on
0 Comments